A new analysis of 759 adults with retinal vein occlusion and macular edema found that two commonly used eye injections, ranibizumab and bevacizumab, work equally well at improving vision and reducing swelling after six months of treatment.
The analysis combined results from several studies comparing the two drugs directly. Both drugs are injected into the eye to treat macular edema, a buildup of fluid that can blur vision. The main measure was change in best-corrected visual acuity, a standard eye test. After six months, the difference between the drugs was tiny: less than one letter on an eye chart, which is not considered meaningful.
The drugs also performed similarly on other measures. The thickness of the central macula, the part of the retina responsible for sharp vision, improved by about the same amount with both drugs. And the proportion of eyes that gained at least 15 letters on the eye chart was nearly identical.
Safety profiles were broadly similar, with rare systemic events being infrequent. However, the evidence for these rare events is uncertain, so doctors and patients should weigh this when choosing a treatment.
Overall, this analysis provides moderate confidence that the two drugs are comparable for visual outcomes, but low to very low confidence for rare adverse events. Patients should discuss their options with their eye doctor to decide which treatment is best for them.
